ID   CHLA-10
AC   CVCL_6583
SY   CHLA10
DR   cancercelllines; CVCL_6583
DR   Cell_Model_Passport; SIDM01542
DR   Cosmic; 930038
DR   DepMap; ACH-001029
DR   GEO; GSM1676328
DR   GEO; GSM1701625
DR   GEO; GSM4368463
DR   GEO; GSM5359634
DR   GEO; GSM5359635
DR   GEO; GSM5359636
DR   GEO; GSM5359637
DR   GEO; GSM5359638
DR   GEO; GSM5359639
DR   GEO; GSM5362864
DR   GEO; GSM5362865
DR   GEO; GSM5362866
DR   GEO; GSM5362867
DR   GEO; GSM5362868
DR   GEO; GSM5362869
DR   GEO; GSM5363941
DR   GEO; GSM5363942
DR   GEO; GSM5363943
DR   GEO; GSM5363944
DR   GEO; GSM5363945
DR   Wikidata; Q54812148
RX   DOI=10.5282/edoc.27750;
RX   PubMed=11212268;
RX   PubMed=15289350;
RX   PubMed=20922763;
RX   PubMed=24312454;
RX   PubMed=26351324;
RX   PubMed=28196595;
RX   PubMed=36476851;
WW   Info; ESCLA; -; https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?option=about_dscope
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
WW   Provider; CCR; -; https://www.cccells.org/PDF_Files/Brain/CHLA-10%20Cell%20Line%20Data%20Sheet.pdf
WW   Provider; CCR; -; https://www.cccells.org/tables/Ewings.php
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Ewing Sarcoma Cell Line Atlas (ESCLA).
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Doubling time: 24 hours (PubMed=20922763); 32 hours (PubMed=24312454).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3508; EWSR1 + HGNC; HGNC:3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=36476851).
CC   Omics: Genomics; ChIP-seq; FLI1.
CC   Omics: Genomics; ChIP-seq; H3K27ac.
CC   Omics: Genomics; ChIP-seq; H3K27me3.
CC   Omics: Genomics; ChIP-seq; H3K4me3.
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Transcriptomics; RNAseq; Single cell.
CC   Derived from site: Metastatic; Thoracic lymph duct; UBERON=UBERON_0007644.
ST   Source(s): COG; PubMed=20922763; PubMed=24312454
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 12,14
ST   D19S433: 12,13
ST   D21S11: 28,29
ST   D2S1338: 20
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 9,10
ST   D8S1179: 10,13
ST   FGA: 23
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 16
DI   NCIt; C3716; Primitive neuroectodermal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M150 ! CHLA-9
SX   Female
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 22
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=11212268;
RA   Thompson P.M., Maris J.M., Hogarty M.D., Seeger R.C., Reynolds C.P.,
RA   Brodeur G.M., White P.S.;
RT   "Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36
RT   or at other tumor suppressor loci in neuroblastoma.";
RL   Cancer Res. 61:679-686(2001).
//
RX   PubMed=15289350; DOI=10.1158/0008-5472.CAN-04-0377;
RA   Batra S., Reynolds C.P., Maurer B.J.;
RT   "Fenretinide cytotoxicity for Ewing's sarcoma and primitive
RT   neuroectodermal tumor cell lines is decreased by hypoxia and
RT   synergistically enhanced by ceramide modulators.";
RL   Cancer Res. 64:5415-5424(2004).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801; PMCID=PMC3005554;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=24312454; DOI=10.1371/journal.pone.0080060; PMCID=PMC3846563;
RA   May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L.,
RA   Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.;
RT   "Characterization and drug resistance patterns of Ewing's sarcoma
RT   family tumor cell lines.";
RL   PLoS ONE 8:e80060.1-e80060.10(2013).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476;
RA   Teicher B.A., Polley E.C., Kunkel M.W., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=36476851; DOI=10.1016/j.celrep.2022.111761; PMCID=PMC10333306;
RA   Orth M.F., Surdez D., Faehling T., Ehlers A.C., Marchetto A.,
RA   Grossetete-Lalami S., Volckmann R., Zwijnenburg D.A., Gerke J.S., Zaidi S.,
RA   Alonso J., Sastre A., Baulande S., Sill M., Cidre-Aranaz F., Ohmura S.,
RA   Kirchner T., Hauck S.M., Reischl E., Gymrek M., Pfister S.M., Strauch K.,
RA   Koster J., Delattre O., Grunewald T.G.P.;
RT   "Systematic multi-omics cell line profiling uncovers principles of
RT   Ewing sarcoma fusion oncogene-mediated gene regulation.";
RL   Cell Rep. 41:111761.1-111761.28(2022).
//